Skip to main content

BeiGene Shares Rise on Analyst Estimates and News of a Cancer Cure Trial

Shares of biopharmaceutical research firm BeiGene Ltd. (Nasdaq: BGNE) shot up almost 10 percent Wednesday on news of a new cancer treatment and an optimistic report by influential investment firm Maxim Group, which raised its price target for the commercial-stage research group by 20 percent, from $120 to $144 per share.
http://www.capitalwatch.com/article-1710-1.html

AUDIENCES

SUBJECTS

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino